In $900M+ deal, rare disease biotechs team up on RNA therapies for CNS developmental disorders
Two biotechs that have built their reputations in rare disease research signed a new collaboration Monday morning aiming to develop three new RNA-based therapies. And the deal could be worth nearly $1 billion in biobucks if every milestone is met.
Acadia Pharmaceuticals and Stoke Therapeutics will team up on the treatments in rare genetic neurodevelopmental diseases of the CNS, the companies announced. Up first will be the recently discovered SYNGAP1 syndrome, followed by Rett syndrome (MECP2) and an undisclosed target the biotechs say is of mutual interest.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.